The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Open accessAbstract
BACKGROUND: Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of recurrence after radical resection. Whether the use of mitotane is beneficial as an adjuvant treatment has been controversial. Our aim was to evaluate the efficacy of adjuvant mitotane in prolonging recurrence-free survival. METHODS: We performed a retrospective analysis involving 177 patients with adrenocortical cancer who had undergone radical surgery at 8 centers in Italy and 47 centers in Germany between 1985 and 2005. Adjuvant mitotane was administered to 47 Italian patients after radical surgery (mitotane group), whereas 55 Italian patients and 75 German patients (control groups 1 and 2, respectively) did not receive adjuvant treatment after surgery. RESULTS: Baseline features in the mitotane group and the control group from Italy were similar; the German patients were significantly older (P=0.03) and had more stage I or II adrenocortical carcinomas (P=0.02) than did patients in the mitotane group. Recurrence-free survival was significantly prolonged in the mitotane group, as compared with the two control groups (median recurrence-free survival, 42 months, as compared with 10 months in control group 1 and 25 months in control group 2). Hazard ratios for recurrence were 2.91 (95% confidence interval [CI], 1.77 to 4.78; P<0.001) and 1.97 (95% CI, 1.21 to 3.20; P=0.005), respectively. Multivariate analysis indicated that mitotane treatment had a significant advantage for recurrence-free survival. Adverse events associated with mitotane were mainly of grade 1 or 2, but temporary dose reduction was needed in 13% of patients. CONCLUSIONS: Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421
Dackiw, A. P. B., Lee, J. E., Gagel, R. F., & Evans, D. B. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0030-7 · Cited by 387
Schulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366
An eleven-year experience with adrenocortical carcinoma.
Pommier, R. F., & Brennan, M. F. (1992) · PubMed · Cited by 332
Haak, H., Hermans, J., van de Velde, C., Lentjes, E., Goslings, B., Fleuren, G.-J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationElse, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citation(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.463 · Cited by 676
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 436
Self-citationUpdate in Adrenocortical Carcinoma
Fassnacht, M., Kroiss, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Self-citationMolecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
“The best evidence for a role of adjuvant treatment derives from a large retrospective study by Terzolo and colleagues”
BackgroundSelf-citationde Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382
Clinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349
Self-citationMajor Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection
Beuschlein, F., Weigel, J., Saeger, W., Kroiss, M., Wild, V., Daffara, F., Libé, R., Ardito, A., Al Ghuzlan, A., Quinkler, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3182 · Cited by 342
Self-citationKerkhofs, T. M. A., Verhoeven, R. H. A., Van der Zwan, J. M., Dieleman, J., Kerstens, M. N., Links, T. P., Van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 341
Fassnacht, M., Berruti, A., Baudin, E., Demeure, M. J., Gilbert, J., Haak, H., Kroiss, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 339
Self-citationAdrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 331
Self-citationAdrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
Ayala-Ramirez, M., Jasim, S., Feng, L., Ejaz, S., Deniz, F., Busaidy, N., Waguespack, S. G., Naing, A., Sircar, K., Wood, C. G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0519 · Cited by 293
(2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0050 · Cited by 292
Brix, D., Allolio, B., Fenske, W., Agha, A., Dralle, H., Jurowich, C., Langer, P., Mussack, T., Nies, C., Riedmiller, H., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.06.024 · Cited by 286
Self-citationHaluska, P., Worden, F., Olmos, D., Yin, D., Schteingart, D., Batzel, G. N., Paccagnella, M. L., de Bono, J. S., Gualberto, A., & Hammer, G. D. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1083-9 · Cited by 197
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma
Barlaskar, F. M., Spalding, A. C., Heaton, J. H., Kuick, R., Kim, A. C., Thomas, D. G., Giordano, T. J., Ben-Josef, E., & Hammer, G. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1456 · Cited by 189
Radiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189
Self-citationImpact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma
Reibetanz, J., Jurowich, C., Erdogan, I., Nies, C., Rayes, N., Dralle, H., Behrend, M., Allolio, B., & Fassnacht, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182367ac3 · Cited by 176
Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2676 · Cited by 173
Self-citationProspective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly
Daffara, F., De Francia, S., Reimondo, G., Zaggia, B., Aroasio, E., Porpiglia, F., Volante, M., Termine, A., Di Carlo, F., Dogliotti, L., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0103 · Cited by 167
Self-citationGrubbs, E. G., Callender, G. G., Xing, Y., Perrier, N. D., Evans, D. B., Phan, A. T., & Lee, J. E. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0716-x · Cited by 158
Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154
Self-citationThe role of surgery in the management of recurrent adrenocortical carcinoma
Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154
Self-citationKroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148
Self-citationGaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Self-citationTerzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0242 · Cited by 134
“4 operative mitotane treatment was associated with a significantly reduced risk of recurrence and death in a large series of patients with radically operated ACC (9, 10).”
BackgroundSelf-citationBevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Self-citationAdjuvant and definitive radiotherapy for adrenocortical carcinoma
Sabolch, A., Feng, M., Griffith, K., Hammer, G., Doherty, G., & Ben-Josef, E. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.04.030 · Cited by 115
Habra, M. A., Ejaz, S., Feng, L., Das, P., Deniz, F., Grubbs, E. G., Phan, A., Waguespack, S. G., Ayala-Ramirez, M., Jimenez, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2367 · Cited by 101
Validation of the prognostic role of the “Helsinki Score” in 225 cases of adrenocortical carcinoma
Duregon, E., Cappellesso, R., Maffeis, V., Zaggia, B., Ventura, L., Berruti, A., Terzolo, M., Fassina, A., Volante, M., & Papotti, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2016.09.035 · Cited by 98
“Beyond its diagnostic role, the Weiss Score also possesses prognostic significance [7], because high Weiss Score tumors generally display an aggressive clinical behavior [8], although this finding was not confirmed in other papers [17,18].”
ResultSelf-citationUrine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma
Chortis, V., Bancos, I., Nijman, T., Gilligan, L. C., Taylor, A. E., Ronchi, C. L., O’Reilly, M. W., Schreiner, J., Asia, M., Riester, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz141 · Cited by 93
“recurred, a rate that is similar to previous retrospective studies (19,27), which suggests that our patient”
ResultVanbrabant, T., Fassnacht, M., Assie, G., & Dekkers, O. M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0450 · Cited by 91
[131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma
Hahner, S., Kreissl, M. C., Fassnacht, M., Haenscheid, H., Knoedler, P., Lang, K., Buck, A. K., Reiners, C., Allolio, B., & Schirbel, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2765 · Cited by 87
Self-citationPlasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma
Schweitzer, S., Kunz, M., Kurlbaum, M., Vey, J., Kendl, S., Deutschbein, T., Hahner, S., Fassnacht, M., Dandekar, T., & Kroiss, M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0782 · Cited by 85
Self-citationResponse to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma
Gonzalez, R. J., Tamm, E. P., Ng, C., Phan, A. T., Vassilopoulou-Sellin, R., Perrier, N. D., Evans, D. B., & Lee, J. E. (2007) · Surgery · doi:10.1016/j.surg.2007.09.006 · Cited by 84
Volante, M., Terzolo, M., Fassnacht, M., Rapa, I., Germano, A., Sbiera, S., Daffara, F., Sperone, P., Scagliotti, G., Allolio, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2692 · Cited by 69
Self-citationKiseljak-Vassiliades, K., Bancos, I., Hamrahian, A., Habra, M. A., Vaidya, A., Levine, A. C., & Else, T. (2020) · Endocrine Practice · doi:10.4158/dscr-2020-0567 · Cited by 66
“These observational studies demonstrated that adjuvant mitotane therapy was associated with prolonged recurrence-free survival and possibly greater overall survival when compared to no adjuvant therapy amongst patients with locoregional/stage 3 ACC (Table 5) (53).”
BackgroundTreatment of Cushing disease: overview and recent findings
Giustina, A. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s12952 · Cited by 66
“Because of this property, its primary use is in patients with adrenocortical carcinoma.(41)”
Liver resection and ablation for metastatic adrenocortical carcinoma
Ripley, R. T., Kemp, C. D., Davis, J. L., Langan, R. C., Royal, R. E., Libutti, S. K., Steinberg, S. M., Wood, B. J., Kammula, U. S., Fojo, T., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1564-z · Cited by 62
Sirianni, R., Zolea, F., Chimento, A., Ruggiero, C., Cerquetti, L., Fallo, F., Pilon, C., Arnaldi, G., Carpinelli, G., Stigliano, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2374 · Cited by 58
Zatelli, M. C., Gentilin, E., Daffara, F., Tagliati, F., Reimondo, G., Carandina, G., Ambrosio, M. R., Terzolo, M., & degli Uberti, E. C. (2010) · Endocrinology · doi:10.1210/en.2009-1404 · Cited by 57
Self-citationResponse to radiation therapy in adrenocortical carcinoma
Hermsen, I. G. C., Groenen, Y. E., Dercksen, M. W., Theuws, J., & Haak, H. R. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346675 · Cited by 42
Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism
Russo, M., Scollo, C., Pellegriti, G., Cotta, O. R., Squatrito, S., Frasca, F., Cannavò, S., & Gullo, D. (2016) · Clinical Endocrinology · doi:10.1111/cen.12868 · Cited by 36
Tripto-Shkolnik, L., Blumenfeld, Z., Bronshtein, M., Salmon, A., & Jaffe, A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2839 · Cited by 27
Medical Therapy for Cushing’s Syndrome in the Twenty-first Century
Tritos, N. A., & Biller, B. M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.01.006 · Cited by 24
Metadata
- Authors
- Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., Reimondo, G., Bollito, E., Papotti, M., Saeger, W., Hahner, S., Koschker, A.-C., Arvat, E., Ambrosi, B., Loli, P., Lombardi, G., Mannelli, M., Bruzzi, P., Mantero, F., Allolio, B., Dogliotti, L., & Berruti, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-07
- Volume
- 356
- Issue
- 23
- Pages
- 2372-2380
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164015349
- Cited by
- 764
- References
- 32
- FWCI
- 40.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.